Nine out of 27 patients in Remdesivir improved

15 cases are 'no change'

Of the 27 COVID-19 patients in Korea who took Remdesivir, 9 cases improved out of 27 patients with severe change.

 

The positive effect was about 30%, which is only a numerical example and is still under professional review.

 

Deputy General Manager Kwon Joon-Wook, the Central Disease Control Headquarters of the KCDC (Director, Eun-kyeong Jung), briefly explained the current status of domestic medications for Remdesivir at the regular briefing session during the day.

 

Currently, the Central Disease Control Headquarters sent a request for special import to the Gilead Korea branch, which is a holding company of Remdesivir, and requested urgent import of 360 people for emergency use and 5000 people for preparation for the pandemic.

 

According to Deputy General Manager Kwon, there are a total of 42 COVID-19 patients currently receiving Remdesivir.

 

A total of 27 patients were able to detect the change in severity because the comparison between the administration group and the non-administration group was not yet completed.

 

Nine out of 27 cases improved.

 

However, he explained, "It is not yet known whether this improvement is due to Remdesivir or the patient's own symptomatic therapy or immunity." It was found that 15 cases were hard to judge the effect or the condition did not change, and three cases were worse.

 

Regarding this, he emphasized again, "This is only a numerical situation, and it is necessary to seek professional judgment from the central clinical committee for the effectiveness of the treatment." Meanwhile, the Central Disease Control Headquarters applied for Remdesivir to 23 hospitals for 42 seriously ill patients, and has now completed supply to all 42 patients.